Local heat plus 3% hydrogen peroxide for stubborn viral warts
Official title: Randomized Single-blind Parallel Controlled Clinical Trial of Hyperthermia Combined With Topical 3% Hydrogen Peroxide for Refractory Viral Warts
Run by First Hospital of China Medical University · NCT07565350 · Data updated 2026-11-12
This will try a combination of local heat and topical 3% hydrogen peroxide on people whose viral warts have not cleared after at least two prior treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | First Hospital of China Medical University Academic / other |
| Locations | 2 sites (Shenyang, Liaoning and 1 other locations) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | October 1, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | May 4, 2026 |
| Trial ID | NCT07565350 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with viral warts lasting two or more years who have not responded to at least two prior treatment methods and who can consent and attend follow-up visits.
✕Probably not a fit
People allergic to local hyperthermia or hydrogen peroxide, those with serious comorbid illnesses that preclude participation, or those unable to attend scheduled treatments and follow-up are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional program combines infrared local hyperthermia (about 44°C ± 2°C for 30 minutes per session) with topical 3% hydrogen peroxide applied to refractory viral warts. Participants are those with a disease course of two years or longer who have failed at least two prior treatments such as topical agents, cryotherapy, or laser. Treatments are delivered at the hospital site using a commercial infrared device and topical applications, with clinical follow-up to document wart clearance and recurrence. Safety exclusions include allergy to heat or hydrogen peroxide and inability to complete follow-up.
Why it matters
Potential benefit: If successful, the approach could clear persistent warts and lower recurrence using a noninvasive, low-cost combination therapy.
How similar studies have gone: Previous work shows thermotherapy can stimulate local immune responses and help clear warts, while topical hydrogen peroxide has supportive tissue-level effects, but the specific combined approach has limited prior clinical data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- 1: Patients with a disease course of ≥2 years who have failed to respond to ≥2 treatment methods (such as topical ointments, cryotherapy, laser therapy, etc.) 2: The subject or their legal guardian is able to understand and sign the informed consent form/agree to participate in the study. Exclusion Criteria: * 1: The subject or their legal guardian is unable to understand and refuses to sign the informed consent form / refuses to participate in the study 2: Individuals allergic to local hyperthermia or hydrogen peroxide; 3: Subjects with tumors or other serious diseases are unable to complete this clinical study; 4: Due to personal or other objective reasons, it is not possible to ensure timely treatment and follow-up.
Where it's running
-
Infrared hyperthermia device (Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China)
Shenyang, Liaoning, China Recruiting -
Infrared hyperthermia device (Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China)
Shenyang, Liaoning, China Recruiting
Study contacts
- Study coordinator: Xinghua Gao
- Email: gaobarry@hotmail.com
- Phone: 024-83282524
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.